E-LIB Suche - Ergebnisse für: Parivar, Kourosh

1

An Investigation in the Comparability of the Exposure and R..:

Wang, Diane D. ; Yu, Yanke ; Fukuhara, Kei...
The Journal of Clinical Pharmacology. 64 (2024) 5 - p. 609-618 , 2024

2

Optimizing benefit/risk in oncology: Review of post-marketi..:

Soltantabar, Pooneh ; Lon, Hoi-Kei ; Parivar, Kourosh..
Critical Reviews in Oncology/Hematology. 182 (2023) - p. 103913 , 2023

Link: https://doi.org/10.1016/..

3

Tumor growth inhibition modeling to support the starting do..:

Fostvedt, Luke K. ; Nickens, Dana J. ; Tan, Weiwei.
CPT: Pharmacometrics & Systems Pharmacology. 11 (2022) 9 - p. 1256-1267 , 2022

Link: https://doi.org/10.1002/..

4

Analysis of US Food and Drug Administration Oncology Approv..:

Yang, Derek Z. ; Alhadab, Ali ; Parivar, Kourosh..
Clinical Pharmacology & Therapeutics. 112 (2021) 4 - p. 782-790 , 2021

Link: https://doi.org/10.1002/..

5

Discordance Between Child‐Pugh and National Cancer Institut..:

Elmeliegy, Mohamed ; Yang, Derek Z. ; Salama, Engie..
The Journal of Clinical Pharmacology. 61 (2020) 1 - p. 105-115 , 2020

Link: https://doi.org/10.1002/..

6

Evaluation of the potential effect of dacomitinib, an EGFR ..:

Tan, Weiwei ; Giri, Nagdeep ; Quinn, Susan..
Investigational New Drugs. 38 (2019) 3 - p. 874-884 , 2019

Link: https://doi.org/10.1007/..

7

Population pharmacokinetics of inotuzumab ozogamicin in rel..:

Garrett, May ; Ruiz-Garcia, Ana ; Parivar, Kourosh..
Journal of Pharmacokinetics and Pharmacodynamics. 46 (2019) 3 - p. 211-222 , 2019

Link: https://doi.org/10.1007/..

8

Predicting Overall Survival and Progression-Free Survival U..:

Lim, Hyeong-Seok ; Sun, Wan ; Parivar, Kourosh.
The AAPS Journal. 21 (2019) 2 - p. , 2019

Link: https://doi.org/10.1208/..

9

Population pharmacokinetic and pharmacodynamic analysis of ..:

Wang, Erjian ; Kang, Dongwoo ; Bae, Kyun-Seop...
The Journal of Clinical Pharmacology. 54 (2014) 10 - p. 1108-1116 , 2014

Link: https://doi.org/10.1002/..

10

Fixed Dosing Versus Body Size—Based Dosing of Therapeutic P..:

Zhang, Shuzhong ; Shi, Rong ; Li, Chunze..
The Journal of Clinical Pharmacology. 52 (2012) 1 - p. 18-28 , 2012

Link: https://doi.org/10.1177/..

11

Elimination of non-reactive and weakly reactive human α1-ac..:

Parivar, Kourosh ; Tolentino, Lorna ; Taylor, Glyn.
Journal of Pharmacy and Pharmacology. 44 (2011) 5 - p. 447-450 , 2011

Link: https://doi.org/10.1111/..

12

Fixed Dosing Versus Body Size—Based Dosing of Monoclonal An..:

Wang, Diane D. ; Zhang, Shuzhong ; Zhao, Hong..
The Journal of Clinical Pharmacology. 49 (2009) 9 - p. 1012-1024 , 2009

Link: https://doi.org/10.1177/..

13

The effect of mild and moderate hepatic impairment on the p..:

Sarapa, Nenad ; Britto, Margaret R. ; Mainka, Michelle B..
European Journal of Clinical Pharmacology. 61 (2005) 4 - p. 247-256 , 2005

Link: https://doi.org/10.1007/..

14

Pharmacokinetics of eltanolone following bolus injection an..:

Parivar, Kourosh ; Wessén, Arne ; Widman, Marianne.
Journal of Pharmacokinetics and Biopharmaceutics. 24 (1996) 6 - p. 535-549 , 1996

Link: https://doi.org/10.1007/..

15

Concentration-Effect Relationships of Eltanolone Given as a..:

Wessen, Arne ; Parivar, Kourosh M. ; Widman, Marianne..
Anesthesiology. 84 (1996) 6 - p. 1317-1326 , 1996

Link: https://doi.org/10.1097/..